Search tips
Search criteria 


Logo of ccforumBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleCritical CareJournal Front Page
Crit Care. 2010; 14(Suppl 1): P512.
Published online 2010 March 1. doi:  10.1186/cc8744
PMCID: PMC2934138

Extraction and purification of 1-hydroxymidazolam glucuronide from ultrafiltrate


We developed a technique for detection of MDZ and 1-hydroxymidazolam glucuronide (1-OHMG). No commercial source of 1-OHMG prevented assay development. 1-OHMG had pharmacological activity and is renally excreted. We postulated that ultrafiltrate (UFR) would be rich in 1-OHMG. We describe a method to purify 1-OHMG from UFR.


Ethics approval was granted. To purify, UFR was extracted on a C-18 column, it was washed and eluted. HPLC-MS separation was performed. The 1-OHMG (mol. wt 517/518 in MS) was desiccated and re-dissolved four times to maximise purity. Electrospray (ESI) mass spectrometry (MS) characterised 1-OHMG. The purity was calculated using NMR. A calibration plot of 1-OHMG, MDZ and DZP (internal standard) for HPLC-MS was performed.


1-OHMG identity was confirmed using MS/MS (Figure (Figure1).1). Two milligrams of 1-OHMG was purified from 5,000 ml UFR. The 1-OHMG was 98% pure (NMR). The extinction coefficient was identical to MDZ. The calibration plot resulted in correlation of 0.912. The assay was applied into clinical practice, to report sera and UFR levels.

Figure 1
Centroided MS of purified 1-OHMG.


We were able to extract and purify an active drug metabolite from UFR. Five litres of UFR resulted in 2 mg 1-OHMG. This is a potentially rich source of drugs or drug metabolites, allowing pharmacokinetic studies greatly required in critical illness.


  • McKenzie. et al. Differentiating MDZ oversedation from neurological damage in the intensive care unit. Crit Care. 2005;9:32–33. doi: 10.1186/cc3010. [PMC free article] [PubMed] [Cross Ref]

Articles from Critical Care are provided here courtesy of BioMed Central